Faeth Therapeutics, Inc. (FTH)
19.50
+0.70
(+3.72%)
USD |
NASDAQ |
Oct 19, 15:47
Faeth Therapeutics Shareholders Equity (Quarterly) : 179.72M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 179.72M |
| March 31, 2026 | 191.19M |
| December 31, 2025 | 18.59M |
| September 30, 2025 | 23.01M |
| June 30, 2025 | 27.31M |
| March 31, 2025 | 31.99M |
| December 31, 2024 | 38.39M |
| September 30, 2024 | 45.78M |
| June 30, 2024 | 52.19M |
| March 31, 2024 | 58.47M |
| December 31, 2023 | 64.90M |
| September 30, 2023 | 71.00M |
| June 30, 2023 | 79.20M |
| March 31, 2023 | 94.85M |
| Date | Value |
|---|---|
| December 31, 2022 | 103.41M |
| September 30, 2022 | 113.99M |
| June 30, 2022 | 125.92M |
| March 31, 2022 | 135.31M |
| December 31, 2021 | 146.51M |
| September 30, 2021 | 155.21M |
| June 30, 2021 | 163.12M |
| March 31, 2021 | 171.25M |
| December 31, 2020 | 15.89M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -21.12M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Opus Genetics, Inc. | -12.99M |
| Nuvectis Pharma, Inc. | 9.082M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 189.31M |
| Total Liabilities (Quarterly) | 9.581M |
| Debt to Equity Ratio | 0.0033 |
| Current Ratio | 19.69 |
| Net Debt Paydown Yield | 0.08% |